




Patent Docket P0790C4D1C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Jardieu et al.  Serial No.: 10/727,383  Filed: December 2, 2003  For: METHOD FOR TREATING MULTIPLE SCLEROSIS	Group Art Unit: To be assigned  Examiner: To be assigned  CUSTOMER NO: 09157
	<b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on  March 2, 2004  Janet Tse

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(X) **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). Those patent(s) or publication(s) which are marked with an asterisk (\*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office

10/727,383

in a prior application Serial Nos. 08/287,055; 08/432,543; and 08/766,008, filed 8 August 1994; 2 May 1995 and 13 December 1996 (respectively) and relied upon in this application for an earlier filing date under 35 USC §120.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) (Required)

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: March 2, 2004

By: Lee K. Tan

Lee K. Tan, Ph.D.

Reg. No. 39,447

Telephone No. (650) 225-4462

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P0790C4D1C2

Serial No.

10/727,383

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Jardieu et al.

Filing Date

02 Dec 2003

Group

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	4,797,277	10.01.89	Arfors			
	* 2	5,002,869	26.03.91	Schlossman et al.			
	* 3	5,071,964	10.12.91	Dustin et al.			
	* 4	5,235,049	10.08.93	McClelland			
	* 5	5,284,931	08.02.94	Springer et al.			27.04.90
	* 6	5,292,636	08.03.94	Kung et al.			09.11.89
	* 7	5,403,919	04.04.95	Butcher			
	* 8	5,475,091	12.12.95	Springer et al.			25.01.94
	* 9	5,538,724	23.07.96	Butcher et al.			23.07.96
	* 10	5,622,700	22.04.97	Jardieu et al.			
	* 11	5,690,933	25.11.97	Cobbold et al.			12.08.94
	* 12	5,762,933	09.06.98	Mawas et al.			17.10.94
	* 13	5,854,070	29.12.98	Rose			
	* 14	6,030,947	29.02.00	Corbi et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	* 15	15509/88	27.07.89	AUSTRALIA			
	* 16	A-15518/88	11.10.88	AUSTRALIA			
	* 17	AU-B-57621/90	03.01.91	AUSTRALIA			
	* 18	2,008,368	13.06.91	CANADA			
	* 19	289,949	11.11.88	EPO			
	* 20	346,078	13.12.89	EPO			
	* 21	379,904	01.08.90	EPO			
	* 22	387,668	19.09.90	EPO			
	* 23	90529	26.06.94	IL			
	* 24	WO 88/06592	07.09.88	PCT			
	* 25	WO 90/08187	26.07.90	PCT			
	* 26	WO 90/10652	20.09.90	PCT			
	* 27	WO 90/15076	13.12.90	PCT			
	* 28	WO 90/15152	13.12.90	PCT			
	* 29	WO 91/16927	14.11.91	PCT			
	* 30	WO 91/16928	14.11.91	PCT			
	* 31	WO 91/18011	28.11.91	PCT			
	* 32	WO 92/22653	23.12.92	PCT			
	* 33	WO 93/06864	15.04.93	PCT			

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0790C4D1C2	Serial No. 10/727,383			
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Jardieu et al.				
				Filing Date 02 Dec 2003	Group			
<b>FOREIGN PATENT DOCUMENTS</b>								
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes      No	
	* 34	WO 94/02175	03.02.94	PCT				
	* 35	WO 94/04188	03.03.94	PCT				
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>								
	* 36	Armitage et al., "The Clinical Trial of FK 506 as Primary and Rescue Immunosuppression in Pediatric Cardiac Transplantation" <u>Transplantation Proceedings</u> 23(6):3058-3060 (December 1991)						
	* 37	Babany et al., "Evaluation of the in vivo Dose-Response Relationship of Immunosuppressive Drugs Using a Mouse Heart Transplant Model: Application of Cyclosporine" <u>The Journal of Pharmacology and Experimental Therapeutics</u> 244(1):259-262 (1988)						
	* 38	Barker et al., "Keratinocytes as Initiators of Inflammation" <u>Lancet</u> 337:211-214 (January 26, 1991)						
	* 39	Baume et al., "Failure of a CD18/Anti-LFA1 Monoclonal Antibody Infusion to Prevent Graft Rejection in Leukemic Patients Receiving T-Depleted Allogeneic Bone Marrow Transplantation" <u>Transplantation</u> 47(3):472-474 (March 1989)						
	* 40	Benjamin et al., "Mechanisms of Monoclonal Antibody-Facilitated Tolerance Induction: A Possible Role for the CD4(L3T4) and CD11a (LFA-1) Molecules in Self-Non-Self Discrimination" <u>European Journal of Immunology</u> 18:1079-1088 (1988)						
	* 41	Berlin et al., "Monoclonal Antibodies Against Human T Cell Adhesion Molecules-Modulation of Immune Function in Nonhuman Primates" <u>Transplantation</u> 53(4):840-849 (1992)						
	* 42	Blakeslee, "New Technique in Lab Prevents Rejection of Organ Transplants" <u>The New York Times</u> pps. B6 (March 10, 1992)						
	* 43	Busing et al., "Is Long-Term Therapy Without Cyclosporin A (CsA) Indispensable or Dangerous? One-Year Results of a Prospective Randomized Trial" <u>Transplantation Proceedings</u> 21(1):1601-1603 (February 1989)						
	* 44	Campbell, "Intercellular Adhesion Molecule 1 is Induced on Isolated Endocrine Islet Cells by Cytokines but not by Reovirus Infection" <u>Proc. Natl. Acad. Sci. USA</u> 86:4282-4286 (1989)						
	* 45	Carpenter et al., "Prophylactic Use of Monoclonal Anti-IL-2 Receptor Antibody in Cadaveric Renal Transplantation" <u>American Journal of Kidney Diseases</u> XIV(5):54-57 (November 1989)						
	* 46	Cobbold et al., "Therapy With Monoclonal Antibodies by Elimination of T-cell Subsets in vivo" <u>Nature</u> 312(6):548-551 (December 1984)						
	* 47	Cosimi et al., "Immunosuppression of Cynomolgus Recipients of Renal Allografts to R6.5, a Monoclonal Antibody to Intercellular Adhesion Molecule-1" <u>In Leukocyte Adhesion Molecules</u> , Springer-Verlag pps. 274-281 (1988)						
	* 48	Cosimi et al., "In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts" <u>The Journal of Immunology</u> 144(12):4604-4612 (June 15, 1990)						
	* 49	Cunningham, "Anomalous Features of Allogeneic Reactions" <u>Understanding Immunology</u> (Chapter 10), New York:Academic Press pps. 158-159 (1978)						
	* 50	Cyclosporine Label, "Product Information" <u>Physicians Desk Reference</u> 49(1995):2183-2186 (1995)						
	* 51	Dantal et al., "Use of Monoclonal Antibodies in Human Transplantation" <u>Current Opinion in Immunology</u> 3:740-747 (1991)						
	* 52	Davignon et al., "Monoclonal Antibody to a Novel Lymphocyte Function-Associated Antigen (LFA-1): Mechanism of Blockade of T Lymphocyte-Mediated Killing and Effects on Other T and B Lymphocyte Functions" <u>The Journal of Immunology</u> 127(2):590-595 (August 1981)						
Examiner					Date Considered			

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0790C4D1C2	Serial No. 10/727,383
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Jardieu et al.	
				Filing Date 02 Dec 2003	Group
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*	53	Dustin et al., "Induction By IL 1 and Interferon- $\gamma$ : Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (ICAM-1)" <u>The Journal of Immunology</u> 137(1):245-254 (July 1, 1986)			
*	54	Edgington, "How Sweet It Is: Selectin-Mediating Drugs" <u>Bio/Technology</u> 10:383-389 (April 1992)			
*	55	Fekete et al., "Involvement of Lymphocyte Function-Associated Antigen-1 (LFA-1) But Not ICAM-1 in a Radioactive Leukocyte Cell-Mediated Immunity (LA-CMI) Assay" <u>J. Clin. Lab. Immunol.</u> 31:145-149 (1990)			
*	56	First et al. <u>Clin. Transplant</u> 2:185-189 (1988)			
*	57	Fischer et al., "Prevention of Graft Failure by an Anti-HLFA-1 Monoclonal Antibody in HLA-Mismatched Bone-Marrow Transplantation" <u>Lancet</u> 2:1058-1061 (November 8, 1986)			
*	58	Fischer et al., "Reduction of Graft Failure by a Monoclonal Antibody (Anti-LFA-1 CD11a) After HLA Nonidentical Bone Marrow Transplantation in Children with Immunodeficiencies, Osteopetrosis, and Fanconi's Anemia" <u>Blood</u> 77(2):249-256 (January 15, 1991)			
*	59	Fischer et al., "Role of the LFA-1 Molecule in Cellular Interactions Required For Antibody Production in Humans" <u>The Journal of Immunology</u> 136(9):3198-3203 (May 1, 1986)			
*	60	Fischer, "Anti-LFA-1 Antibody as Immunosuppressive Reagent in Transplantation" <u>Chem. Immunol.</u> 50:89-97 (1991)			
*	61	Goebeler et al., "Expression of Intercellular Adhesion Molecule-1 in Murine Allergic Contact Dermatitis" <u>Int. Arch. Allergy Appl. Immunol.</u> 93:294-299 (1990)			
*	62	Harris et al., "Therapeutic Antibodies - The Coming of Age" <u>TIBTECH</u> 11:42-44 (February 1993)			
*	63	Heagy et al., "Potent Ability of Anti-LFA-1 Monoclonal Antibody to Prolong Allograft Survival" <u>Transplantation</u> 37:520-523 (1984)			
*	64	Herbert et al., "Strategies of Monoclonal Antibody Therapy That Induce Permanent Tolerance of Organ Transplants" <u>Transplantation</u> 46:128S-134S (August 1988)			
*	65	Hildreth et al., "A Human Lymphocyte-associated Antigen Involved in Cell-mediated Lympholysis" <u>European Journal of Immunology</u> 13:202-208 (1983)			
*	66	Hourmant et al., "Administration of an Anti-CD11a Monoclonal Antibody in Recipients of Kidney Transplantation" <u>Transplantation</u> 58(3):377-380 (August 1994)			
*	67	Hutchings et al., "Transfer of Diabetes in Mice Prevented by Blockade of Adhesion-Promoting Receptor on Macrophages" <u>Nature</u> 348:639-642 (December 13, 1990)			
*	68	Isaacs et al., "Humanised Monoclonal Antibody Therapy for Rheumatoid Arthritis" <u>Lancet</u> 340:748-752 (September 26, 1992)			
*	69	Isobe et al., "Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1" <u>Science</u> pps. 1125-1127 (February 1992)			
*	70	Jendrisak et al., "Prolongation in Murine Cardiac Allograft Survival With Monoclonal Antibodies to LFA-1, ICAM-1, and CD4" <u>Transplantation Proceedings</u> 25(1):825-827 (February 1993)			
*	71	Jensen et al., "Pediatric Renal Transplantation Under FK 506 Immunosuppression" <u>Transplantation Proceedings</u> 23(6):3075-3077 (December 1991)			
*	72	Kahana et al., "OKT3 Prophylaxis Versus Conventional Drug Therapy: Single-Center Perspective, Part of a Multicenter Trial" <u>American Journal of Kidney Diseases</u> XIV(5):5-9 (November 1989)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0790C4D1C2	Serial No. 10/727,383
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Jardieu et al.	
				Filing Date 02 Dec 2003	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	* 73	Komori et al., "Role of ICAM-1 and LFA-1 in Cardiac Allograft Rejection of the Rat" <u>Transplantation Proceedings</u> 25(1):831-832 (February 1993)			
	* 74	Krensky et al., "The Functional Significance, Distribution, and Structure of LFA-1, LFA-2, and LFA-3: Cell Surface Antigens Associated with CTL-Target Interactions" <u>The Journal of Immunology</u> 131(2):611-616 (August 1983)			
	* 75	Kuypers and Roos, "Leukocyte Membrane Adhesion Proteins LFA-1, CR3 and p150,95: A Review of Functional and Regulatory Aspects" <u>Res. Immunol.</u> 140:461-486 (1989)			
	* 76	Lakey et al., "Prevention of Recurrence of Insulin-Dependent Diabetes Mellitus in Islet Cell-Transplanted Diabetic NOD Mice Using Adjuvant Therapy" <u>Transplantation Proceedings</u> 24(6):2848 (December 1992)			
	* 77	Larson et al., "Structure and Function of Leukocyte Integrins" <u>Immunological Reviews</u> 114:181-217 (1990)			
	* 78	LeMauff et al., "Effect of Anti-LFA1 (CD11a) Monoclonal Antibodies in Acute Rejection in Human Kidney Transplantation" <u>Transplantation</u> 52(2):291-296 (August 1991)			
	* 79	Levinsky, "Recent Developments in Bone Marrow Transplantation" <u>Clinical Immunol. and Immunopathol.</u> 50(1):S124-S132 (1989)			
	* 80	Lo et al., "Two Leukocyte Receptors (CD11a/CD18 and CD11b/CD18) Mediate Transient Adhesion to Endothelium by Binding to Different Ligands" <u>The Journal of Immunology</u> 143(10):3325-3329 (November 15, 1989)			
	* 81	Maraninchi et al., "Anti LFA-1 Monoclonal Antibody for the Prevention of Graft Rejection After T Cell-depleted HLA-matched Bone Marrow Transplantation for Leukemia in Adults" <u>Bone Marrow Transplantation</u> 4:147-150 (1989)			
	* 82	Masroor et al., "Monoclonal Antibodies in Organ Transplantation: An Overview" <u>Transplant Immunology</u> 2:176-189 (1994)			
	* 83	McCabe et al., "sICAM-1 Enhances Cytokine Production Stimulated by Alloantigen" <u>Cellular Immunology</u> 150:364-375 (1993)			
	* 84	McMurray et al., "Adhesion molecules in autoimmune disease" <u>Seminars in Arthr. Rheum</u> 25:215-233 (1996)			
	* 85	Mentzer et al., "LFA-1 Membrane Molecule in the Regulation of Homotypic Adhesions of Human B Lymphocytes" <u>The Journal of Immunology</u> 135(1):9-11 (July 1985)			
	* 86	Monaco, "Biological Immunosuppression: Polyclonal Antilymphocyte Sera, Monoclonal Antibody, & Donor-Specific Antigen Biological Immunosuppression: Polyclonal Antilymphocyte Sera, Monoclonal Antibody, & Donor-Specific Antigen" <u>Organ Transplantation &amp; Replacement</u> (Ch. 5), Cerilli, Phil.:Lippincott pps.			
	* 87	Morris et al., "A Study of the Contrasting Effects of Cyclosporine, FK 506, and Rapamycin on the Suppression of Allograft Rejection" <u>Transplantation Proceedings</u> 22(4):1638-1641 (August 1990)			
	* 88	Nakakura et al., "An Anti-Adhesion Molecule (LFA-1, CD11a) Monoclonal Antibody Suppresses Ongoing Rejection and Prolongs Heart Allograft Survival Indefinitely Without Lymphocyte Depletion" <u>The Journal of Heart and Lung Transplantation</u> 11(1):130 (Jan 1992)			
	* 89	Nakakura et al., "Potent and Effective Prolongation by Anti-LFA-1 Monoclonal Antibody Monotherapy of Non-Primarily Vascularized Heart Allograft Survival in Mice Without T Cell Depletion" <u>Transplantation</u> 55(2):412-417 (February 1993)			
	* 90	Nickoloff et al., "Cellular Localization of Interleukin-8 and its Inducer, Tumor Necrosis Factor-alpha in Psoriasis" <u>American Journal of Pathology</u> 138(1):129-140 (January 1991)			
	* 91	Nickoloff, "Keratinocyte Intercellular Adhesion Molecule-1 (ICAM-1) Expression Precedes Dermal T Lymphocytic Infiltration in Allergic Contact" <u>Am. J. Pathol</u> 135:1045-1053 (1989)			
	* 92	Nickoloff, "Role of Interferon-gamma in Cutaneous Trafficking of Lymphocytes with Emphasis on Molecular and Cellular Adhesion Events" <u>Arch Dermatol.</u> 124:1835-1843 (1988)			
Examiner			Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0790C4D1C2	Serial No. 10/727,383
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Jardieu et al.	
				Filing Date 02 Dec 2003	Group
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
	* 93	O'Reilly et al., "Characterization of Pancreatic Islet Cell Infiltrates in NOD Mice: Effect of Cell Transfer and Transgene Expression" <u>European Journal of Immunology</u> 21:1171-1179 (1991)			
	* 94	Perez et al., "In Vivo Infusion of Anti LFA-1 Antibody in HLA Non-identical Bone Marrow Transplantation in Children: Serum Concentrations and Biological Effects" <u>Bone Marrow Transplantation</u> 4:379-384 (1989)			
	* 95	Qin et al., "Complete Freund's Adjuvant-Induced T Cells Prevent the Development and Adoptive Transfer of Diabetes in Nonobese Diabetic Mice" <u>The Journal of Immunology</u> 150(5):2072-2080 (March 1, 1993)			
	* 96	Rizova et al., "The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin" <u>J. Dermatol. Science</u> 7(1):1-13 (1994)			
	* 97	Sanders et al., "Characterization of the Physical Interaction Between Antigen-Specific B and T Cells" <u>The Journal of Immunology</u> 137(8):2395-2404 (October 15, 1986)			
	* 98	Schorlemmer et al., "Therapeutic Effects of 15-Deoxyspegualin in Acute and Chronic Relapsing Experimental Allergic Encephalomyelitis (EAE) as Models for Multiple Sclerosis (MS)" <u>Drugs Exptl. Clin. Res.</u> XVII(10/11):461-469 (1991)			
	* 99	Schroeder et al., "Antimurine Antibody Formation Following OKT3 Therapy" <u>Transplantation</u> 49:48-51 (January 1990)			
	*100	Shapiro et al., "FK 506 in Clinical Kidney Transplantation" <u>Transplantation Proceedings</u> 23(6):3065-3067 (December 1991)			
	*101	Shield et al., "The Reuse of OKT3 After Previous Rejection or Induction Therapy in Cadaveric Renal Transplantation" <u>American Journal of Kidney Disease</u> 14(5 (Suppl. 2)):35-38 (1989)			
	*102	Shizuru et al., "Immunotherapy of the Nonobese Diabetic Mouse: Treatment with an Antibody to T-Helper Lymphocytes" <u>Science</u> 240:659-662 (1988)			
	*103	Stoppa et al., "Anti-LFA1 Monoclonal Antibody (25.3) for Treatment of Steroid-resistant Grade III-IV Acute Graft-versus-host Disease" <u>Transplant International</u> 4:3-7 (1991)			
	*104	Tilney et al., "Chronic Rejection-An Undefined Conundrum" <u>Transplantation</u> 52(3):389-398 (Sep. 1991)			
	*105	Trager et al., "Cardiac Allograft Prolongation in Mice Treated with Combined Postransplantation Total-Lymphoid Irradiation and Anti-L3T4 Antibody Therapy" <u>Transplantation</u> 47(4):587-591 (April 1989)			
	*106	Tufveson, "New Immunosuppressants: Testing and Development in Animal Models and the Clinic: with Special Reference to DSG" <u>Immunol. Reviews</u> 136:99-109 (1993)			
	*107	Twaddell, "Clinical Experience with rhuMAB HER2 in Metastatic Breast Cancer" <u>Antibody Engineering</u> (Abstract) Sixth IBC Internatio (1995)			
	*108	Van Brunt, "Therapeutic Antibodies (Finally) Come of Age" <u>BioWorld Financial Watch</u> 3(29):1-11 (July 17, 1995)			
	*109	Van Dijken et al., "Evidence That Anti-LFA-1 in vivo Improves Engraftment and Survival After Allogeneic Bone Marrow Transplantation" <u>Transplantation</u> 49(5):882-886 (May 1990)			
	*110	Waid et al., "T10B9.1A-31 Anti-T-Cell Monoclonal Antibody: Preclinical Studies and Clinical Treatment of Solid Organ Allograft Rejection" <u>American Journal of Kidney Diseases</u> XIV(5):61-70 (November 1989)			
	*111	Waldmann, "Immune Receptors: Targets for Therapy of Leukemia/Lymphoma, Autoimmune Diseases and for the Prevention of Allograft Rejection" <u>Annu. Rev. Immunol.</u> 10:675-704 (1992)			
	*112	Waldmann, "Manipulation of T-Cell Responses with Monoclonal Antibodies" <u>Ann. Rev. Immunol.</u> 7:407-444 (1989)			
Examiner			Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

